Dipeptide Alanyl Glutamine and Postoperative Insulin Resistance in Colon Carcinoma Patients

Colon Carcinoma Clinical Trial

— AIRCo  

Official title:

Dipeptide Alanyl Glutamine and Postoperative Insulin Resistance in Colon Carcinoma Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00922688
• Other study ID #: AIRCo05.02.2009/2
• Status: Recruiting
• Phase: N/A
• First received: June 16, 2009
• Last updated: July 20, 2011
• Start date: December 2010
• Est. completion date: May 2013

Study information

• Verified date: November 2010
• Source: Medical Center Alkmaar
• Contact: Hamit Cakir, MD
• Phone: 0031725484444
• Email: h.cakir[@]mca.nl
• Is FDA regulated: No
• Health authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
• Study type: Interventional

Clinical Trial Summary

Rationale: It is well known that insulin resistance occurs after mediocre and intensive surgery, such as colon cancer surgery. Disturbances in insulin action negatively affect the postoperative recovery, either by prolonging the capacity of the body to regain normal function, or by increasing the metabolic stress and the risk for complications. Several studies have shown that focusing therapies on improving insulin resistance is successful. Experimental studies have shown that antioxidant agents, like glutamine (a precursor of glutathione), improve insulin sensitivity. The hypothesis of this study is that perioperative parenteral or enteral administration of glutamine, given as the dipeptide alanyl-glutamine, will reduce or prevent postoperative insulin resistance in colon cancer patients. The study will also be focused on the different routes of administration, because of the expected differential metabolic effects.

Objective: The investigators' primary objective is to study whether intravenous or enteral administration of the dipeptide alanyl-glutamine will reduce or prevent postoperative insulin resistance in colon cancer patients.

Study design: A double-blinded, placebo controlled randomised, pilot study at the Surgery Department of the Medical Center Alkmaar.

Study population: Thirty patients of male gender and any ethnicity, who will undergo elective open abdominal colon surgery for colon cancer, aged 18-75 years.

Intervention: Patients will receive dipeptide alanyl-glutamine intravenously or enterally, starting 24 hours prior to surgery, until 24 hours after surgery in the dosage of 0.5 g/kg/day, or saline (control group), for the same period of time.

Main study parameters/endpoints: The main study parameter is postoperative insulin resistance. Secondary study parameters are lipolysis, oxidative stress and glucoregulatory hormones. Muscle, liver and fat biopsies will be taken to study insulin sensitive as well as inflammatory pathways.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: May 2013
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age between 18 and 75 years

• Colon cancer patients scheduled for elective open abdominal surgery

• Capable of giving informed consent

Exclusion Criteria:

• Patients who are participating in another clinical trial

• Unable to receive oral intake

• Major malabsorption disorder of the gut

• Patients with diabetes mellitus

• BMI above 30 kg/m2

• Use of certain medication: thyroid medication, corticosteroids, diuretic medication

• Known bleeding disorders or increased PTT and or APTT

• Any medical condition except for colon cancer

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Carcinoma
• Colon Carcinoma
• Colonic Neoplasms
• Insulin Resistance

Intervention

Drug:
• Dipeptide Alanyl-Glutamine
Intravenous supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
• Placebo
Intravenous and enteral supplementation of placebo is started 24 hours prior to surgery and continued 24 hours postoperatively.
• Dipeptide Alanyl-Glutamine
Enteral supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.

Locations

Country	Name	City	State
Netherlands	Medical Center Alkmaar	Alkmaar	Noord holland

Sponsors (1)

Lead Sponsor	Collaborator
Medical Center Alkmaar

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The effect of intravenously and enterally administered dipeptide alanyl-glutamine preoperatively on postoperative insulin resistance in colon cancer patients.given, on postoperative insulin resistance in colon cancer patients.		Before and 1 day after surgery	No
Secondary	The effect of the dipeptide alanyl-glutamine on components of the insulin signalling cascade in muscle tissue.		Before and 1 day after surgery	No
Secondary	The effect of the dipeptide alanyl-glutamine on the systemic inflammatory response as well as on inflammatory pathways in muscle.		Before and 1 day after surgery	No
Secondary	The effect of the dipeptide alanyl-glutamine on the amino acid concentration in muscle tissue.		Before and 1 day after surgery	No
Secondary	The effect of the dipeptide alanyl-glutamine on antioxidant/oxidant parameters in the circulating compartment.		Before and 1 day after surgery	No
Secondary	The effect of dipeptide alanyl-glutamine on the inflammatory response in the liver		During surgery	No
Secondary	The effect of dipeptide alanyl-glutamine on lipolysis.		Before and 1 day after surgery	No
Secondary	The effect of dipeptide alanyl-glutamine on key enzymes involved in glucose production.		Before and 1 day after surgery	No